Real world evidence of use of anti-VEGF therapy in Denmark

References

• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56
   PubMed Web of Science ®Google Scholar
• Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014;121:2181-92
   PubMed Web of Science ®Google Scholar
• CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122:2044-52
   PubMed Web of Science ®Google Scholar
• Prunte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016;100:787-95
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81
   PubMed Web of Science ®Google Scholar
• Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016;123:330-6
   PubMed Web of Science ®Google Scholar
• Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014;121:1414-20 e1
   PubMed Web of Science ®Google Scholar
• Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-37 e7
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121:209-19
   PubMed Web of Science ®Google Scholar
• Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-9
   PubMed Web of Science ®Google Scholar
• Varma R, Bressler NM, Suner I, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 2012;119:2108-18
   PubMed Web of Science ®Google Scholar
• Rezaei KA, Stone TW. ASRS Global Trends In Retina. 2014. Available at: https://www.asrs.org/content/documents/2014_global_rends_comprehensivepostmtg.pdf [Last accessed 27 July 2016]
   Google Scholar
• Bek T. Baggrundsnotat for behandling af våd aldersrelateret maculadegeneration (våd AMD) [Danish Treatment Guidelines for treating wet age-related macular degeneration]. 12 November 2013. Available at: http://www.regioner.dk/media/1917/baggrundsnotat-for-behandling-af-vd-aldersrelateret-maculadegeneration-vd-amd.pdf [Last accessed 27 July 2016]
   Google Scholar
• Bek T. Baggrundsnotat for behandling af diabetisk maculaødem [Danish treatment guidelines for treating diabetic macular edema]. 15 April 2015. Available at: http://www.regioner.dk/media/1919/dme-baggrundsnotat-juli-2015.pdf [Last accessed 20 July 2016]
   Google Scholar
• Bek T. Baggrundsnotat for behandling af retinal veneokklusion [Danish treatment guidelines for retinal vein occlusion]. 7 September 2015. Available at: http://www.regioner.dk/media/1922/bgn-rvo-september-2015.pdf [Last accessed 20 July 2016]
   Google Scholar
• Writing Committee for the UKA-RMDEMRUG. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014;121:1092-101
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58 e1
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. Lucentis 10 mg/ml solution for injection. 13 May 2016. Available at: http://www.medicines.org.uk/emc/medicine/19409 [Last accessed 20 July 2016]
   Google Scholar
• Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 2016;30:270-86
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
   PubMed Web of Science ®Google Scholar
• Johnston SS, Wilson K, Huang A, et al. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv Ther 2013;30:1111-27
   PubMed Web of Science ®Google Scholar
• Dugel PU, Griner R, Milnes F, et al. Clinical effectiveness of ranibizumab and aflibercept for neovascular AMD: a retrospective cohort study using electronic medical records from the US. 15th ESASO Retina Academy, Barcelona, Spain, 22–24 October 2015
   Google Scholar
• Ferreira A, Sagkriotis A, Olson M, et al. Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA. PLoS One 2015;10:1-12
   Web of Science ®Google Scholar
• Kiss S, Rajput Y, Quezada Ruiz C, et al. Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year US claims analysis. Investigative Ophthalmology & Visual Science 2016 (Session 324 AMD and anti-VEGF Therapy 2): Program number: 3335
   Google Scholar
• Rasmussen A, Sander B, Larsen M, et al. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections. Acta Ophthalmol doi: 10.1111/aos.13233. Epub 2016 August 18
   Google Scholar
• Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013;91:540-6
   PubMed Web of Science ®Google Scholar
• Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013;7:1849-58
   PubMedGoogle Scholar
• Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 2013;33:474-81
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015;99:220-6
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24 e1
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9
   PubMed Web of Science ®Google Scholar
• Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013;33:1351-8
   PubMed Web of Science ®Google Scholar
• Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014;34:1531-8
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Brandi S, Fuchs J, et al. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol 2015;93:616-20
   PubMed Web of Science ®Google Scholar
• Semoun O, BlancoGaravito R, Cohen SY, et al. A real-world evaluation of frequency of ranibizumab and aflibercept deliveries for treatment naïve patients with neovascular age-related macular degeneration: 12-month results from the French LYVE survey. Investig Ophthalmol Vis Sci 2016;3340:D0143
   Google Scholar
• George A, Reitzer V, Bellamy JP. Comparison of anti-VEGF ranibizumab and aflibercept: a 18 months, real-life study in naïve patients. Investig Ophthalmol Vis Sci 2016;539:A0176
   Google Scholar
• Gillies MC, Walton R, Arnold J, et al. Twelve months outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: observational study data. Investig Ophthalmol Vis Sci 2016;523:A0160
   Google Scholar
• Reich O, Bachmann LM, Faes L, et al. Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data. Risk Manag Healthc Policy 2015;8:55-62
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee DW, Chang YS, et al. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-016-3353-7. Epub 2016 May 26
   Web of Science ®Google Scholar